title: Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.
abstract: Vaginal and vulvar cancers do not account for a large proportion of gynecologic malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors and display levels of dysplasia before progression to invasive disease. Human Papillomavirus (HPV) is a known causative agent of such dysplasia and can be detected now more readily than ever with adequate recognition techniques and provider awareness. Although HPV vaccination is still lagging compared to other recommended childhood vaccinations, the impact on lower genital tract neoplasia is promising. The bivalent and quadrivalent vaccines have been shown to be efficacious and the newest nonavalent vaccine should add even more of impact on coverage of cancer-causing HPV types. Although it is still early to show true clinical and population-based disease reduction due to low disease incidence and relatively short time of vaccine availability, the potential is noteworthy.
authors.affiliation: a Division of Gynecologic Oncology, Medical University of South Carolina , Charleston , SC , USA.
authors.forename: Tommy R
authors.initials: TR
authors.lastname: Buchanan
authors.affiliation: a Division of Gynecologic Oncology, Medical University of South Carolina , Charleston , SC , USA.
authors.forename: Whitney S
authors.initials: WS
authors.lastname: Graybill
authors.affiliation: a Division of Gynecologic Oncology, Medical University of South Carolina , Charleston , SC , USA.
authors.forename: Jennifer Young
authors.initials: JY
authors.lastname: Pierce
mesh_terms: D005260:Female; D006801:Humans; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D016896:Treatment Outcome; D014611:Vaccination / Q000706:statistics & numerical data*; D014625:Vaginal Neoplasms / Q000453:epidemiology* / Q000401:mortality*; D014846:Vulvar Neoplasms / Q000453:epidemiology* / Q000401:mortality*
chemical_list: D053918:Papillomavirus Vaccines
keywords: disease reduction; human paillomavirus vaccination; vaginal cancer; vulvar cancer